Type your tag names separated by a space and hit enter

The consumption of omega-3 polyunsaturated fatty acids improves clinical outcomes and prognosis in pancreatic cancer patients: a systematic evaluation.

Abstract

This study was aimed to systematically evaluate results of trials examining the effects of omega-3 polyunsaturated fatty acid (n-3 PUFA) consumption on body weight, lean body mass, resting energy expenditure, and overall survival in pancreatic cancer patients. We searched Medline, Pubmed, Embase, and Cochrane databases. We selected randomized controlled trials of n-3 PUFA vs. conventional nutrition in unresectable pancreatic cancer patients. We analyzed our data using the Cochrane statistical package RevMan 5.1. Eleven trials met our inclusion criteria. There was a significant increase in body weight [weighted mean difference (WMD) = 0.62; 95% confidence interval (CI), 0.54-0.69, P < 0.00001) and lean body mass (WMD = 0.96; 95% CI, 0.86-1.06, P < 0.00001), a significant decrease in resting energy expenditure (WMD = -29.74; 95% CI, -55.89-3.59, P = 0.03), and an increase in overall survival (130-259 days vs. 63-130 days) in unresectable pancreatic cancer patients who consumed an oral nutrition supplement enriched with n-3 PUFAs compared to those who consumed conventional nutrition. This preliminary study suggests that n-3 PUFAs are safe and have a positive effect on clinical outcomes and survival in pancreatic cancer patients.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    a Department of Oncology, Beijing Friendship Hospital , Capital Medical University , Beijing , China.

    , ,

    Source

    Nutrition and cancer 67:1 2015 pg 112-8

    MeSH

    Basal Metabolism
    Cachexia
    Combined Modality Therapy
    Fatty Acids, Omega-3
    Food, Fortified
    Humans
    Pancreatic Neoplasms
    Paraneoplastic Syndromes
    Prognosis
    Randomized Controlled Trials as Topic

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't
    Review

    Language

    eng

    PubMed ID

    25425246

    Citation

    Ma, Ying-Jie, et al. "The Consumption of Omega-3 Polyunsaturated Fatty Acids Improves Clinical Outcomes and Prognosis in Pancreatic Cancer Patients: a Systematic Evaluation." Nutrition and Cancer, vol. 67, no. 1, 2015, pp. 112-8.
    Ma YJ, Yu J, Xiao J, et al. The consumption of omega-3 polyunsaturated fatty acids improves clinical outcomes and prognosis in pancreatic cancer patients: a systematic evaluation. Nutr Cancer. 2015;67(1):112-8.
    Ma, Y. J., Yu, J., Xiao, J., & Cao, B. W. (2015). The consumption of omega-3 polyunsaturated fatty acids improves clinical outcomes and prognosis in pancreatic cancer patients: a systematic evaluation. Nutrition and Cancer, 67(1), pp. 112-8. doi:10.1080/01635581.2015.976315.
    Ma YJ, et al. The Consumption of Omega-3 Polyunsaturated Fatty Acids Improves Clinical Outcomes and Prognosis in Pancreatic Cancer Patients: a Systematic Evaluation. Nutr Cancer. 2015;67(1):112-8. PubMed PMID: 25425246.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - The consumption of omega-3 polyunsaturated fatty acids improves clinical outcomes and prognosis in pancreatic cancer patients: a systematic evaluation. AU - Ma,Ying-Jie, AU - Yu,Jing, AU - Xiao,Jing, AU - Cao,Bang-Wei, Y1 - 2014/11/25/ PY - 2014/11/27/entrez PY - 2014/11/27/pubmed PY - 2015/9/4/medline SP - 112 EP - 8 JF - Nutrition and cancer JO - Nutr Cancer VL - 67 IS - 1 N2 - This study was aimed to systematically evaluate results of trials examining the effects of omega-3 polyunsaturated fatty acid (n-3 PUFA) consumption on body weight, lean body mass, resting energy expenditure, and overall survival in pancreatic cancer patients. We searched Medline, Pubmed, Embase, and Cochrane databases. We selected randomized controlled trials of n-3 PUFA vs. conventional nutrition in unresectable pancreatic cancer patients. We analyzed our data using the Cochrane statistical package RevMan 5.1. Eleven trials met our inclusion criteria. There was a significant increase in body weight [weighted mean difference (WMD) = 0.62; 95% confidence interval (CI), 0.54-0.69, P < 0.00001) and lean body mass (WMD = 0.96; 95% CI, 0.86-1.06, P < 0.00001), a significant decrease in resting energy expenditure (WMD = -29.74; 95% CI, -55.89-3.59, P = 0.03), and an increase in overall survival (130-259 days vs. 63-130 days) in unresectable pancreatic cancer patients who consumed an oral nutrition supplement enriched with n-3 PUFAs compared to those who consumed conventional nutrition. This preliminary study suggests that n-3 PUFAs are safe and have a positive effect on clinical outcomes and survival in pancreatic cancer patients. SN - 1532-7914 UR - https://www.unboundmedicine.com/medline/citation/25425246/full_citation L2 - http://www.tandfonline.com/doi/full/10.1080/01635581.2015.976315 DB - PRIME DP - Unbound Medicine ER -